Furthermore, after treatment, the MPO level in fenofibrate-treated patients was significantly lower than the control group, a result which comes in agreement with the findings of a prior clinical study that demonstrated the antioxidant role of fenofibrate and its capacity to improve vascular endothelial function through significant reduction of MPO levels in patients with type 2 diabetes mellitus (Nita et al. 2014). Here, MPO is linked to diabetes mellitus.